Robert W. Baird Lowers Danaher (NYSE:DHR) Price Target to $268.00

Danaher (NYSE:DHR) had its price objective reduced by Robert W. Baird from $277.00 to $268.00 in a report released on Tuesday morning. They currently have an overweight rating on the conglomerate’s stock.

Other research analysts have also issued research reports about the stock. Barclays lowered their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Citigroup decreased their target price on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. TD Cowen upped their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus lifted their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $285.81.

Danaher Price Performance

DHR opened at $247.77 on Tuesday. The firm has a market cap of $178.96 billion, a price-to-earnings ratio of 47.29, a PEG ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average price is $235.75 and its 200 day moving average price is $253.65. Danaher has a 12-month low of $225.42 and a 12-month high of $281.70.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Hedge Funds Weigh In On Danaher

A number of large investors have recently bought and sold shares of the company. Fort Pitt Capital Group LLC raised its holdings in Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after purchasing an additional 7,421 shares in the last quarter. Good Life Advisors LLC purchased a new position in shares of Danaher during the 3rd quarter worth approximately $217,000. ORG Partners LLC lifted its holdings in shares of Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after buying an additional 2,559 shares during the period. Harvest Portfolios Group Inc. grew its holdings in Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after acquiring an additional 2,465 shares during the period. Finally, Stifel Financial Corp raised its position in Danaher by 1.3% in the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after acquiring an additional 11,216 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.